Dagogo-Jack reviewed alarming data on the damage prediabetes can inflict even decades before a diabetes diagnosis and offered guidance to the internal medicine audience.
All News
Advertisement
Advertisement
Your daily dose of the clinical news you may have missed.
William Lewis, MD, discussed the importance of photo-documentation, referral indicators, efficacy of various treatments, and other topics.
ACP 2025. A quick look at 2 topics in dermatology rounded out a Multiple Small Feedings of the Mind session at the 2025 American College of Physicians annual meeting.
ACP 2025. Ruth Etzioni, PhD, discussed evidence-based approaches to screening for patients at average risk, start and stop criteria, MRI for follow-up screening, and other topics.
In a new position paper, the ACP calls for policy action to address rural health disparities, improve access to care, and strengthen the rural health care workforce.
Research That Is Changing Endocrinology: Advances, Challenges, and The Future, with Irl B Hirsch, MD
ACP 2025: Irl B Hirsch, MD, reviewed findings from 8 papers published in 2024 that he believes have made or will make a difference in the practice or understanding of the clinical area.
ACP 2025. Thomas Martens, MD, Gregg Simonson, PhD, and Libby Johnson, RDN, LD, CDCES explained the benefits of CGM, how to interpret data, and then adjust treatment accordingly.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Advertisement
Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
Family physician and researcher Mark Ebell, MD, discusses the clinical implications, efficacy, and role of gepotidacin in UTI management.
Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.
In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.
Your daily dose of the clinical news you may have missed.
ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.
The Women’s Sexual Health Test (Visby Medical) delivers results in approximately 30 minutes using a vaginal swab.
Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.
Your daily dose of the clinical news you may have missed.
New research shows that treating both men and women with topical and oral antibiotics lowers the odds of bacterial vaginosis recurrence by more than half.
Advertisement
Advertisement
Advertisement
